Diehl et al. [16], in a pilot study of 18 patients with metastatic colorectal cancer who were indicated as being candidates for surgical resection or radiofrequency ablation, showed that cfDNA from plasma samples can be isolated and oncogenic mutations (APC, KRAS, TP53) can be detected in all tested patients using the BEAMing PCR-based technology. This evidence concerns the gene TP53 and metastatic colorectal cancer.